6-(Methylamino)hexane-1,3,4,5-tetrol

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 6-(Methylamino)hexane-1,3,4,5-tetrol
• 英文别名: 6-(methylamino)hexane-1,3,4,5-tetrol
• 化学式: C₇H₁₇NO₄
• 分子量: 179.21
• InChiKey: UTJJESQWBFVHEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  93
• 氢给体数：
  5
• 氢受体数：
  5

文献信息

• [EN] CONTRAST AGENTS<br/>[FR] AGENTS DE CONTRASTE
  申请人：BRACCO IMAGING SPA

  公开号：WO2017098038A1

  公开（公告）日：2017-06-15

  The present invention relates to new class of functionalized macrocycles capable of chelating paramagnetic metal ions, their chelated complexes with metal ions and the use thereof as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis.5

  本发明涉及一类新型的功能化大环化合物，能够螯合顺磁性金属离子，以及它们与金属离子形成的螯合络合物，以及将其用作对比剂的用途，特别适用于磁共振成像（MRI）分析。
• [EN] A PROCESS FOR PREPARATION OF FOSAPREPITANT DIMEGLUMINE AND AN INTERMEDIATE THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION DE FOSAPRÉPITANT DIMÉGLUMINE ET D'UN INTERMÉDIAIRE DE CELUI-CI
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2017093899A1

  公开（公告）日：2017-06-08

  The present invention relates to a novel process for the preparation of intermediate of fosaprepitant dimeglumine. The present invention particularly relates to a process for the preparation of fosaprepitant dibenzyl ester, an intermediate of fosaprepitant dimeglumine, which is simple, easy to handle on commercial scale and efficient.

  本发明涉及一种新型的制备磷酸阿帕替坦二甲胍中间体的方法。本发明特别涉及一种制备磷酸阿帕替坦二苄酯的方法，该方法简单、易于在商业规模上操作并且高效。
• CONTRAST AGENTS
  申请人：Bracco Imaging SpA

  公开号：EP3386953B1

  公开（公告）日：2020-10-21
• N-METHYL-N-((2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL)-(Z)-OCTADEC-9-ENAMID ZUR VERRINGERUNG DER AUGENREIZUNG
  申请人：Werner & Mertz GmbH

  公开号：EP3496699B1

  公开（公告）日：2020-05-13
• Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases
  申请人：AMICUS THERAPEUTICS, INC.

  公开号：US20210251971A1

  公开（公告）日：2021-08-19

  The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining α-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of α-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.